Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Nov 4, 2013 (13 years ago)

Soliris (eculizumab)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Presence of Particulate Matter: Failed the appearance test for the presence of visible particles.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Soliris (eculizumab) Concentrated Solution for Intravenous Infusion Only, 300 mg/30 mL (10 mg/mL), 30 mL Single-Use Vial, Rx only, Manufactured by: Alexion Pharmaceuticals, Inc., Cheshire, CT 06410, NDC 25682-001-01, UPC 3 25682-001-01 6.

Affected NDC 25682-0001-01

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Soliris
Eculizumab
NDC 25682-0001
300 mg/30mL Injection, Solution, Concentrate
Intravenous
Alexion Pharmaceuticals Inc. Rx
Recalling firm
Alexion Pharmaceuticals, Inc.
NDC code
25682-001-01
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1049-2014 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Alexion Pharmaceuticals, Inc.

All 2013 recalls
Class I · High risk

Soliris (eculizumab)

Presence of Particulate Matter: Product failed the appearance for the presence of visible particles under labeled storage condition.

Terminated Particulate / foreign matter Alexion Pharmaceuticals, Inc. NDC 25682-001-01 D-1512-2014

Other particulate / foreign matter recalls from 2013

All particulate / foreign matter recalls
Class II · Moderate risk

Carisoprodol Tablets

Presence of Foreign Substance; metal particulates were visually observed in the tablets.

Terminated Particulate / foreign matter Watson Laboratories Inc NDC 0591-5513-05 D-397-2014
Class I · High risk

Lidocaine HCl Injection

Presence of Particulate Matter- Confimed customer complaint of particulates embedded in glass container and in contact with product solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-2066-05 D-1278-2014
Class II · Moderate risk

Propofol Injectible Emulsion

Presence of Particulate Matter: Glass defect located on the interior neck of the vial identified glass surface abrasions and visible embedded particulate matter which could result in the potential for small glass flakes or embedded metal particulate to become dislodged into the solution.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-30 D-1033-2014
Class II · Moderate risk

Carisoprodol IV

Presence of Foreign Substance; heavy metals (chromium, titanium etc) and inactive components of the product were visually observed during routine stability testing.

Terminated Particulate / foreign matter Physicians Total Care, Inc. D-390-2014